Key facts
- This page summarizes Ozan Pamir's Form 4 filing for Niagen Bioscience, Inc. (NAGE).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Jul 2026, 17:17.
Ozan Pamir - 30 Jun 2026 Form 4 Insider Report for Niagen Bioscience, Inc. (NAGE)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- NAGE
- Reported as of
- 30 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Jul 2026, 17:17:37 UTC
- Prior SEC filing
- 24 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeong James Lee, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ozan Pamir filed Form 4 for Niagen Bioscience, Inc. (NAGE) on 08 Jul 2026.
Change
- Previous filing in this sequence was filed on 24 Feb 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001834681
Primary reporting owner
Pamir Ozan
- Relationship
- Chief Financial Officer
- Address
- 10900 WILSHIRE BLVD. SUITE 600, LOS ANGELES
- Signature
- /s/ Jeong James Lee, Attorney-in-Fact
- Signature date
- 08 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NAGE
transaction
Common Stock
Award
- Transaction value
- Shares
- +4,255
- Change %
- +58%
- Price
- $2.71*
- Shares after
- 11,627
- Date
- 30 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
NAGE
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,220
- Date
- 30 Jun 2026
- Ownership
- The reported securities are held by the reporting person's spouse.
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. The acquisition is exempt under Rule 16b-3(c) and 16b-3(d).